FMED - ETF AI Analysis
Top Page
Fidelity Disruptive Medicine ETF (FMED)
Rating:58Neutral
Price Target:―
Positive Factors
Focused Exposure to Disruptive Medicine
The fund concentrates on innovative health care companies, giving investors targeted access to potential long-term growth in medical technologies and treatments.
Strong Performance from Select Holdings
Some top positions, such as Cogent Biosciences, Bio-Techne, and Moderna, have shown strong gains this year, helping offset weaker names in the portfolio.
Recent Short-Term Momentum
The ETF has delivered a strong gain over the past month, suggesting improving short-term sentiment despite weaker results over longer periods.
Negative Factors
High Sector Concentration in Health Care
With the vast majority of assets in the health care sector, the fund is heavily exposed to swings in one industry rather than being broadly diversified.
Several Weak Top Holdings
Key positions such as Danaher, Intuitive Surgical, Alnylam Pharma, and Insmed have shown weak performance this year, dragging on overall returns.
Negative Year-to-Date Performance with Moderate Fees
The ETF has delivered a weak year-to-date return while charging a mid-range expense ratio, which may feel costly to investors given recent underperformance.
FMED vs. SPDR S&P 500 ETF (SPY)
AUM41.44M
RegionGlobal
Expense Ratio0.50%
Beta0.83
IssuerFidelity
Inception DateJun 12, 2023
Dividend YieldN/A
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume6,365
30 Day Avg. Volume16,746
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
35.95Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering69
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
FMED Summary
The Fidelity Disruptive Medicine ETF (FMED) focuses on innovative healthcare companies, especially in areas like biotechnology, digital health, genomics, and precision medicine. It does not track a traditional index, but instead follows the theme of “disruptive medicine,” aiming to invest in firms driving the future of medical treatments and technology. Well-known holdings include Danaher and Intuitive Surgical, along with Moderna. Someone might invest in FMED for long-term growth potential and to tap into medical breakthroughs. A key risk is that it is heavily concentrated in healthcare stocks, so its price can swing sharply with that sector.
How much will it cost me?The Fidelity Disruptive Medicine ETF (FMED) has an expense ratio of 0.50%, which means you’ll pay $5 per year for every $1,000 invested. This is higher than average because the fund is actively managed, focusing on innovative healthcare companies that require more research and expertise to select.
What would affect this ETF?The Fidelity Disruptive Medicine ETF (FMED) could benefit from ongoing advancements in biotechnology, genomics, and digital health, as well as increased global demand for innovative healthcare solutions. However, it may face challenges from regulatory changes, high research and development costs, and potential market volatility in the healthcare sector. Its global exposure and focus on disruptive medicine make it sensitive to both breakthroughs and setbacks in medical innovation.
FMED Top 10 Holdings
FMED is firmly planted in disruptive healthcare, with a global roster of biotech and medical innovators driving the story. UnitedHealth and Legend Biotech have been rising, giving the fund a steadier backbone alongside the more volatile names. Moderna has been a powerful but choppy engine, helping recent momentum despite its mixed fundamentals. On the other side, Intuitive Surgical, Danaher, and Cogent Biosciences have been lagging, acting like a headwind. Overall, the ETF is concentrated in high-risk, high-reward medical breakthroughs rather than broad, defensive healthcare.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Lifestance Health Group | 4.72% | $1.96M | $3.34B | 61.60% | 61 Neutral | |
| ― | 3.63% | $1.51M | ― | ― | ― | |
| Danaher | 3.35% | $1.39M | $127.96B | -10.25% | 75 Outperform | |
| 10x Genomics | 3.10% | $1.28M | $3.69B | 176.91% | 60 Neutral | |
| Legend Biotech | 3.03% | $1.26M | $6.74B | -2.61% | 46 Neutral | |
| Intuitive Surgical | 2.81% | $1.16M | $146.23B | -19.74% | 78 Outperform | |
| Argenx Se | 2.74% | $1.14M | $55.56B | 54.62% | 79 Outperform | |
| Alnylam Pharma | 2.65% | $1.10M | $38.64B | -8.16% | 60 Neutral | |
| Cogent Biosciences | 2.63% | $1.09M | $5.57B | 367.51% | 37 Underperform | |
| UnitedHealth | 2.37% | $983.05K | $368.30B | 30.30% | 72 Outperform |
FMED Technical Analysis
Positive
―
Price Trends
25.00
Positive
25.31
Positive
25.87
Negative
Market Momentum
0.10
Negative
57.56
Neutral
79.23
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For FMED, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 24.78, equal to the 50-day MA of 25.00, and equal to the 200-day MA of 25.87, indicating a neutral trend. The MACD of 0.10 indicates Negative momentum. The RSI at 57.56 is Neutral, neither overbought nor oversold. The STOCH value of 79.23 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FMED.
FMED Peer Comparison
Comparison Results
Performance Comparison
FMED
Fidelity Disruptive Medicine ETF
25.54
1.70
7.13%
MEDI
Harbor Health Care ETF
―
―
―
TMED
T. Rowe Price Health Care ETF
―
―
―
MEDX
Horizon Kinetics Medical ETF
―
―
―
BMED
Future Health ETF
―
―
―
JDOC
JPMorgan Healthcare Leaders ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents